Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 44Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Stage II Prostate Adenocarcinoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms 1Neoadjuvant Therapy 1Low Risk Prostate Cancer 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Castration Levels of Testosterone 1Carcinoma, Small Cell 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

bicalutamide 4pembrolizumab 1nilutamide 1exemestane 1darolutamide 1cabazitaxel 1apalutamide 1abemaciclib 1Vorinostat 1Triptorelin Pamoate 1Tamoxifen 1Letrozole 1Histamine H2 Antagonists 1Histamine Antagonists 1Goserelin 1Doxorubicin 1Dasatinib 1Cisplatin 1CP protocol 1Aromatase Inhibitors 1Antiemetics 1Anastrozole 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bulbo-Spinal Atrophy, X-Linked × apalutamide × Clear all
NCT04926181 2025-05-15

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
2 enrolled 12 charts
GenitourinaryThoracic

Prostatic Neoplasms, Carcinoma, Small Cell, Bulbo-Spinal Atrophy, X-Linked, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡